Archive | Hot Mandates RSS feed for this section

Hot Mandates: Venture Arm of Foundation

12 Apr

The fund not-for-profit subsidiary of the parent foundation. Launched in 2018 as the venture arm of the foundation and with $72 million under management, the fund focuses on making mission-related investments in companies with projects nearing clinical testing. The fund is geographically agnostic, and has an initial investment allocation range typically between $2M and $5M.

The fund was created to help accelerate life-changing outcomes for people with retinal degenerations through direct mission related investments in therapeutic companies. The mission of the parent foundation is to rapidly drive the research that will lead to preventions, treatments and cures for retinal degenerative diseases – including retinitis pigmentosa, age-related macular degeneration, Usher syndrome and the entire spectrum of retinal degenerative diseases.

The fund thesis is generally focused on therapeutic companies that range from nearing a pre-IND to clinically staged programs focused on inherited retinal disease (IRD) conditions and dry AMD. The fund is unique in that it can leverage the full weight of the parent foundation’s knowledge and resources including: natural history studies, world-class scientific advisory board and clinical consortium. As a result, the fund leverages both internal resources, and investment capital to attract additional investors and is open to using financial instruments including convertible notes, equity, fixed multiple return on investments, and/or royalties, with a preference for ground floor equity investments.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.

Hot Mandates: Impact-Focused Venture Fund

12 Apr

The venture fund is an impact, for-profit venture fund with a philanthropic component based in Burlingame, CA. The fund focuses on early/translational stage investments in the diagnosis and treatment of brain-related diseases. The firm is actively investing from its second fund, which closed in 2017. Initial investments will generally range from $200,000-1 million. The firm prefers to invest in the USA but also considers investing in companies based in Canada. While the fund is a for-profit investor, the firm allocates a portion of its investment returns to brain health charities.

The fund invests in therapeutics, medical devices and diagnostics for brain diseases. The firm prefers to invest in companies at the translational stage development (moving from preclinical to clinic). While the firm will consider investments in any area of brain-related treatment and diagnosis, there is high interest in technologies that provide meaningful approaches to multiple brain disease to benefit patients, including drug delivery across the blood-brain barrier, personalized medicine, and molecularly targeted therapeutics. Investments may be considered in any brain-related disease, and the fund’s previous investments include companies working in the fields of neurodegenerative diseases (including Alzheimer’s disease and other forms of dementia), stroke (ischemic and hemorrhagic), memory disorders, traumatic brain injury, and other diseases of the central nervous system (including Parkinson’s disease, epilepsy and neuropathic pain).

The fund does not have any fixed requirements for companies or management teams. Among other factors, the fund considers the length of time it will take before a company’s products begin to benefit patients, as the fund would prefer that its investments have an impact within a reasonable timeframe. The firm works closely with brain health foundations to source new technologies.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.

Hot Mandates: Foundation Focused on Investing

12 Apr

The foundation was founded in 2017 and looks to accelerate transformation in cancer research through research grants, venture investing, and company creation. The foundation has flexibility when investing and may offer support through a variety of mechanisms, depending on the stage and context of the startup and its scientific programs. The foundation generally invests in Seed to Series B rounds and will invest globally.

The foundation invests only in companies working on cancer, including therapeutics and diagnostics, that hold promise to improve outcomes for cancer patients. The foundation also considers investments aimed at applying a company’s existing technology or platform to the field of cancer. The foundation is especially interested in novel therapeutic targets and precision medicine approaches that have the potential to impact multiple cancer indications.

The foundation has no specific requirements for the company and management team. The foundation may co-lead investments, in which case they will require a board seat. In all other instances, the foundation requires a board observer seat and an SAB observer seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.

Hot Investor Mandate: USA-Based Family Office Invests in Early-Stage Companies Across the Globe, With Strong Interest in Therapeutics Opportunities

8 Apr

A family office based in the USA has several decades of experience in investing in life science companies and taking them public. The firm participates in deals across all stages of development, from seed to mezzanine funding. In early-stage deals, the firm’s initial check size is usually between $250-500K, with potential for follow-on financing as the companies achieve key growth milestones. The firm is actively involved with a well-established angel investor group and makes investments through this group as well. The firm is open to opportunities all across the globe.

The firm seeks to invest broadly across different silos of the life sciences ecosystem, from therapeutics, devices, diagnostics, and digital health. The firm’s strongest interest and expertise lies in biotech, and many of the firm’s investments have been in therapeutics companies. The firm is also open to companies of all stages of development and is indication agnostic, but has significantly higher standards for oversaturated, competitive spaces such as oncology.

The firm has no explicitly stated company or management team requirements. The firm likes to become actively involved in their portfolio companies and supports them with needed resources and advisory services to help them grow.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Asia Cross Border VC Firm Invests in Therapeutics, Devices, and Diagnostics, Open to USA & China-Based Companies

8 Apr

A venture capital firm headquartered in Taiwan currently manages a fund focuses 50% on bio & healthcare-related investments, and outside of life sciences the firm invests in all types of high potential technologies with disruptive potential. The firm primarily seeks investment opportunities in USA, China and Taiwan.

The firm is most interested in novel therapeutics, but also invests in medical devices and diagnostics. Within therapeutics, the firm has invested across various modalities, from traditional small molecule therapeutics to emerging therapies like immunotherapy and cell/gene therapy. The firm is open to pre-IND, early-stage opportunities given they have a valid proof of concept and address an area of unmet medical need. As for medical devices, the firm generally invests in 510k products and open to all types of devices that address unmet medical need.

The firm has no specific company or management team requirements. Though the firm is based in Taiwan, the firm does not require any sort of Taiwan angle or market potential when evaluating cross-border opportunities. The firm is open to leading and co-investing in investment rounds and will most likely seek board representation when acting as the lead investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Western Europe VC Firm Invests Up to €20M in Early-Stage & Growth Stage Life Science Companies Over Company Life Cycle

8 Apr

A leading Venture Capital firm investing in early-and growth stage life science companies has multiple offices in Western Europe. The firm is focused on investing in the most promising life science companies in the fields of biotechnology, therapeutics, medical technology, diagnostics and digital health. With funds totaling EUR 1.0 billion, and more than EUR 430 million committed to life sciences, the firm has been actively supporting world class private companies translating true innovation into successful businesses with exceptional growth. To date, the firm has invested in over 50 innovative life science companies. Initial ticket size ranges between EUR 5-10 million and up to EUR 20 million over the life of the investment.

The firm invests mainly in Europe and selectively in US across five broad areas:  Therapeutics, Medtech, Diagnostics, Digital Health and Biotechnology and R&D tools. Regarding therapeutics, the firm focuses on early-stage companies with preclinical proof of concept data or about to enter the clinic, with a preference for companies developing highly innovative technology platforms, or with early clinical data. In the other fields, the firm prefers companies with product candidates (with strong IP protection) approaching regulatory approval or companies who have already launched a first product and have some early market traction in the single million digit range.

The firm typically requests a board seat and looks for a strong and experienced management team while supporting highly talented entrepreneurs.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Private Investment Firm Seeks Opportunities in Diagnostics, Digital Health, and Platform Technologies in USA & Canada

8 Apr

A private investment firm is looking to make venture investments in emerging fast growth projects. Typical equity investments range from $500,000 to $3 million per deal. The firm will invest in companies across the United States and Canada.

Currently the firm is most interested in areas of personal medicine diagnostics, particularly in genomics and proteomics. Other areas of high interest include, digital health, platform technologies, nutrition, clean environment, and much more selectively drug development and medical devices. The firm has experience in immunology and is more familiar with vaccine and antibody based technologies. The firm is open in terms of indication and considers orphan indications as well but requires strong data and a clear pathway to exit.

The firm invests in privately held companies and will both lead or co-invest. The firm looks to take a board seat in some of its portfolio companies though it is not a requirement. The firm looks for smart and passionate management teams with high levels of experience in the field.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

<span>%d</span> bloggers like this: